OncoPharm FOLFOX (MOSAIC Trial)
10 snips
Dec 13, 2018 This discussion dives into the FOLFOX chemotherapy regimen and its significant impact on treating stage II and III colon cancer. It examines the historical development of 5-FU and clinical trials proving FOLFOX's efficacy and safety. The conversation also highlights the innovative CAPEX regimen, a three-week schedule involving capecitabine, and compares it to traditional treatments. The ongoing evolution in chemotherapy practices aims to improve effectiveness while minimizing side effects, marking important advancements in oncology pharmacy.
AI Snips
Chapters
Transcript
Episode notes
5-FU and Leucovorin History
- 5-FU was discovered in the 1950s, later enhanced by adding leucovorin to improve efficacy.\n- This combination set the foundation for adjuvant chemotherapy in colon cancer before FOLFOX.
Establishment of 5-FU Leucovorin
- Adjuvant 5-FU leucovorin became standard of care after showing survival benefits over earlier regimens.\n- Different 5-FU leucovorin dosing regimens exist, but most showed no difference in survival outcomes.
FOLFOX Regimen Origin
- FOLFOX combines bolus and infusion 5-FU with leucovorin and adds oxaliplatin for improved efficacy.\n- The regimen was pioneered by de Gramont and forms the foundation for modern colon cancer treatment.